Everything we do at BioGene is centred around our mission statement: Helping to significantly improve global health outcomes – but most importantly save lives.
In order to achieve our mission statement we develop pioneering molecular technologies to improve access to diagnostic testing. These technologies make possible simplified decentralised RT-qPCR diagnostic testing direct from crude sample (including whole blood) anywhere in the world without the need for specialist training, facilities or equipment whilst the patient waits in under 30 minutes. We call this unique capability At Patient Testing (APT) and represents true point of care testing. In the wake of past, present and possible future pandemics it has highlighted the dire need of novel technology platforms capable of At Patient Testing (APT).
At BioGene we focus on High Consequence Infectious Diseases (HCID). This involves targeting both neglected diseases and Emerging Infectious Diseases (EIDs). These diseases include ‘Disease X’ which is on the WHO shortlist of blueprint priority diseases and defined as “the knowledge that a serious international epidemic could be caused by a pathogen currently unknown to cause human disease”. We know that future outbreaks of Disease X are inevitable which is what makes our work so integral when it comes to pandemic resilience and supporting future response to emerging High Consequence Infectious Diseases (HCIDs).
Our key stakeholders some of which include healthcare professionals for rapid response to outbreaks of emerging diseases and in the agricultural sector for surveillance of notifiable animal diseases have expressed their need for At Patient Testing (APT). Diseases such as Lassa, Ebola, Marburg, Rift Valley Fever, Crimean Congo Haemorrhagic Fever, PPRV and Foot & Mouth are highly contagious with an extremely high mortality rate.
Therefore, infected patients must be tested, diagnosed, triaged, quarantined and treated as quickly as possible in order to help save their lives and contain the spread of infection. Part of this strategy includes the identification of pre-symptomatic and asymptomatic individuals at the earliest stage of infection to improve patient outcomes and support the breaking of onward transmission chains. Sensitive RT-qPCR based diagnostics facilitates this objective which meet the specified WHO Target Product Profile (TPP).
We develop diagnostic tests not just for human IVD applications but also in-field/penside veterinary testing with a strong focus on zoonotic pathogens which could drive future outbreaks. Proactive surveillance of such pathogens using our platform technology is required to better understand and prevent transmission between species.
With close to 30 years of experience in this specific field we have a firm grasp of what needs to be done to improve global health outcomes and ultimately save lives. We have established a synergistic network of partners around the world who share our mission and recognise the need for embracing and deploying new technologies like CENOS. This includes Public Health England (PHE) who we worked closely with in response to the Ebola epidemic centred in Western Africa. Additionally we have completed veterinary focused projects with The Pirbright Institution (TPI) including testing for Peste des petits ruminants virus (PPRV) and Foot-and-mouth disease virus (FMDV).
It is our goal to provide a solution-based portfolio of products, services and support to each and every one of our customers fulfilling the many needs of our stakeholders across the global laboratory research, diagnostics and molecular biology markets.
BioGene's portable in-field qPCR system CENOS is allows non-expert users to perform gold standard RT-qPCR direct from crude samples whilst the patient waits.